NEW YORK (GenomeWeb News) – Stem cell technology company Cellular Dynamics International and Madison, Wisconsin-based life sciences company Promega today announced plans to collaborate on validating predictive drug discovery toxicity tests that rely on CDI's induced pluripotent stem cells and cytotoxicity and cell viability assays from Promega.
Through the collaboration, the companies plan to combine CDI's iCell Cardiomyocytes — human heart muscle cells derived from induced pluripotent stem cells — with Promega bioassays to come up with a validated, stem cell-based in vitro assay for predicting dangerous or unwanted side effects during the drug discovery and development process.
CDI, a spinout of the University of Wisconsin at Madison, says it has validated a Promega cell-based cytotoxicity assay using the iCell Cardiomyocytes and presented data at scientific conferences supporting the use of Promega's multiplexed biomarker cytotoxicity and cell viability assays for recognizing toxic agents.
CDI and its collaborators in the pharmaceutical industry will reportedly continue testing and validating Promega assays in the hopes of making them part of their drug discovery programs.
In a statement issued today, CDI Chief Commercial Officer Chris Parker said the CDI-Promega collaboration should lead to safer and more effective drug development that hinges on biologically predictive data.